PD-1 Combined With Adjuvant Chemotherapy and Antivascular Therapy Versus Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: TNBC - Triple-Negative Breast Cancer
Interventions: DRUG: epirubicin,cyclophosphamide,paclitaxel,Carrelizumab|DRUG: epirubicin,cyclophosphamide,paclitaxel
Sponsor: Fudan University